Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone510-970-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$84.45 million
Profitability
Miscellaneous
Employees302
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions
What is Sangamo Therapeutics' stock symbol?
Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
How were Sangamo Therapeutics' earnings last quarter?
Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.14. The biopharmaceutical company had revenue of $8.07 million for the quarter, compared to analyst estimates of $27.21 million. Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. View Sangamo Therapeutics' Earnings History.
When is Sangamo Therapeutics' next earnings date?
What price target have analysts set for SGMO?
5 equities research analysts have issued twelve-month target prices for Sangamo Therapeutics' stock. Their predictions range from $11.00 to $24.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 64.6% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.
What is the consensus analysts' recommendation for Sangamo Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sangamo Therapeutics.
What are Wall Street analysts saying about Sangamo Therapeutics stock?
Here are some recent quotes from research analysts about Sangamo Therapeutics stock:
- 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (1/18/2019)
- 2. Wedbush analysts commented, "Neurocrine and collaborator Abbvie announced approval of Orilissa (elagolix) for the management of moderate to severe pain associated with Endometriosis. Abbvie is guiding for the drug to be available in early August. According to Neurocrine mgmt, WAC price is $844.87/ mo for both 150mg QD regimen and 200mg BID regimen. Max treatment duration is 24mo for former and 6mo for latter. We are not making any material changes to our Orilissa sales ests. Neurocrine is entitled to a $40M approval milestone payment in 3Q18 and tiered royalties, which we believe range from 16-20%. Reiterate BUY." (7/24/2018)
Has Sangamo Therapeutics been receiving favorable news coverage?
News headlines about SGMO stock have been trending negative on Sunday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sangamo Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the near future.
Are investors shorting Sangamo Therapeutics?
Sangamo Therapeutics saw a decrease in short interest in April. As of April 30th, there was short interest totalling 13,536,304 shares, a decrease of 11.0% from the April 15th total of 15,208,698 shares. Based on an average trading volume of 1,287,488 shares, the short-interest ratio is currently 10.5 days. Currently, 11.8% of the company's shares are sold short. View Sangamo Therapeutics' Current Options Chain.
Who are some of Sangamo Therapeutics' key competitors?
Some companies that are related to Sangamo Therapeutics include argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Regenxbio (RGNX) and Orchard Therapeutics (ORTX).
What other stocks do shareholders of Sangamo Therapeutics own?
Who are Sangamo Therapeutics' key executives?
Sangamo Therapeutics' management team includes the folowing people:
- Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
- Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
- Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
- Dr. Edward Rebar, Sr. VP & CTO
- Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations
Who are Sangamo Therapeutics' major shareholders?
Sangamo Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.24%), Wasatch Advisors Inc. (5.59%), Wellington Management Group LLP (3.74%), FMR LLC (2.12%), Dimensional Fund Advisors LP (1.32%) and Geode Capital Management LLC (1.09%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.
Which institutional investors are selling Sangamo Therapeutics stock?
SGMO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., BlackRock Inc., First Trust Advisors LP, Trexquant Investment LP, Hsbc Holdings PLC, Frontier Capital Management Co. LLC and Morgan Stanley. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Edward R Conner and Kathy Yi. View Insider Buying and Selling for Sangamo Therapeutics.
Which institutional investors are buying Sangamo Therapeutics stock?
SGMO stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Wasatch Advisors Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC, Bailard Inc., State of Wisconsin Investment Board and Sector Gamma AS. View Insider Buying and Selling for Sangamo Therapeutics.
How do I buy shares of Sangamo Therapeutics?
Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sangamo Therapeutics' stock price today?
One share of SGMO stock can currently be purchased for approximately $9.72.
How big of a company is Sangamo Therapeutics?
Sangamo Therapeutics has a market capitalization of $1.12 billion and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.
What is Sangamo Therapeutics' official website?
How can I contact Sangamo Therapeutics?
Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]
MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
